Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure (a) timely adjustments of medications and (b) access to treatments for people with Parkinson's.

Clinicians are responsible for making prescribing decisions for their patients, taking into account best prescribing practice and the local commissioning decisions of their respective integrated care boards. They are also expected to take account of appropriate national guidance on clinical and cost effectiveness, and are accountable for their prescribing decisions, both professionally and to their service commissioners.

Timely adjustment and optimisation of medicines are important to ensure patients are receiving the most clinically appropriate and effective treatment to support their health and wellbeing. It is also critical in underpinning the six rights of safe medicines management: the right person; right medicine; right route; right dose; right time; and right to decline.

The National Institute of Health and Care Excellence (NICE) is the independent body responsible for translating evidence into authoritative guidance for the health and care system on best practice. The NICE has produced guidance on the management of Parkinson’s disease, which includes recommendations on pharmacological management, including the timing of medicine administration. The NICE has also developed a Quality Standard for Parkinson’s disease that states that adults with Parkinson's disease who are in hospital, or a care home, should take levodopa within 30 minutes of their individually prescribed administration time. Clinicians are expected to take relevant national guidance fully into account when making clinical decisions regarding their patients, including the adjustment of medications.

The Department is aware of supply constraints with one supplier of amantadine 100 milligram capsules used in the management of Parkinson’s disease, however stocks remain available from alternative suppliers to cover demand. The Department has also been notified of a discontinuation of apomorphine (APO-go PFS) 50 milligram/10 millilitre pre-filled syringes from April 2025. Alternative formulations of apomorphine remain available for patients and management guidance has been issued to the National Health Service.